







Atlas Genet Cytogenet Oncol Haematol. 2012; 16(8)  521 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
CRK (v-crk sarcoma virus CT10 oncogene 
homolog (avian)) 
Shinya Tanaka 
Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan (ST) 
 
Published in Atlas Database: March 2012 
Online updated version : http://AtlasGeneticsOncology.org/Genes/CRKID40149ch17p13.html 
DOI: 10.4267/2042/47483 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: CRKII, p40 
HGNC (Hugo): CRK 
Location: 17p13.3 
Note 
CT10 regulator of kinase. 
DNA/RNA 
Note 
Crk belongs to an adaptor family of protein mostly 
composed of SH2 (src homology 2) and SH3 domains. 
Description 
The human genomic DNA sequence contains 3 exons. 
Transcription 
The length of open reading frame of transcript is 912 
mer and translated to a 304 residues protein referred as 
c-Crk-II. By alternative splicing, 610-778 were deleted 
and truncated protein encoding 203 amino acids protein 
as c-Crk-I was generated. Recently, Crk-III which 




Crk-II gene comprises of three exons spanning on chromosome 17p13.3. 
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Tyrosine Y221 (human) of CrkII can be tyrosine phosphorylated and SH2 domain of CrkII binds to pY221 intramolecularly. 
 
 





Crk was originally isolated as avian retrovirus (CT10, 
chicken tumor No. 10) encoding oncoprotein as v-Crk 
(viral Crk, CT10 regulator of kinase). 
Crk-II is composed of SH2-SH3(N)-SH3(C) and 
alternative splicing product Crk-I which deleted 
SH3(C) as SH2-SH3(N). 
Description 
NMR analysis of Crk-I, Crk-II, and phosphorylated 
form of Crk-II (aa 1-231). Crk-I has flexible structure 
of the linker region, thus individual SH2 or SH3 
domain freely access to the targets (data not shown). 
Unphosphorylated form of Crk-II exhibits compact 
structure, and each SH domains were relatively fixed 
around inter SH3 region (designated as ISC: inter SH3 
core; yellow in the figure below). 
In this form, interaction surface of SH3(N) is in the 
semi-closed status. Upon tyrosine phosphorylation of 
Y221, SH2 binds to pY221 and structure is 
dramatically altered and SH3(N) surface is completely 














Signaling adaptor protein which links tyrosine kinases 
and small G proteins. 
Crk transmits signals from extracellular stimuli such as 
growth factors and extracellular matrices. SH2 domain 
of Crk bound to tyrosine phosphorylated peptide motif 
as YXXP. In focal adhesion complex, Crk binds to 
p130Cas which  
possesses six Crk binding consensus sequences and to 
paxillin. Crk activates Fak and transmit signals to PI3 
kinase.  
Crk also binds to growth factor receptors such as EGFR 
or FGF, in addition to downstream signaling scaffold 
protein Gab1 which is mainly activated by HGF.  
CRK transmits signals to small G proteins through its 
SH3 domain binding target C3G and DOCK180 those 
can activate Rap/R-Ras and Rac, respectively, and 
regulates cell growth, adhesion, and motility. 
Crk plays various roles including cell growth, 







Crk is overexpressed in various human cancers 
especially in lung adenocarcinoma and in brain tumor.  
Crk knockdown study demonstrates the essential roles 
for Crk in malignant potentials of various human 
cancers including ovarian cancer, sarcoma, and brain 
tumor.  
Recently, microRNA-126 was shown to suppress lung 
cancer growth by the suppression of Crk expression. 
Crk has been reported to bind to NS1 protein of 
influenza virus type H5N1, CagA protein of 
Helicobacter pylori, and also known to regulate the 
infection of Pseudomonas aeruginosa and Shigella 
flexneri.  
Therefore, Crk can be a therapeutic target molecule for 
cancer and infectious diseases. 
Lung cancer 
Note 
96 cases of lung adenocarcinoma were analyzed by 
using Gene chip and in the cases of stage III, mRNA 
levels of Crk were increased comparing to those of in 
stage I (Beer et al., 2002).  
Affymetrix oligonucleotide arrays were used to analyze 
86 lung adenocarcinomas and 10 uninvolved lung 
tissues, and Crk mRNA expression was increased in 
more advanced (stage III versus stage I), larger (T2-4 
versus T1), and poorly differentiated tumors and in 
tumors from patients demonstrating poor survival 
(Miller et al., 2003).  
Immunohistochemical analysis of Crk-II demonstrated 
that the levels of Crk-II were significantly elevated in 
most of the tumors, particularly in the colon and lung 
cancers. Furthermore, immunoblot analysis using 
human lung cancer cell lines revealed that the 
expression levels of Crk-II were correlated to growth 
rates of cells (Nishihara et al., 2002). 
Prognosis 
Expression of Crk mRNA was increased in patients 
with poor prognosis (P=0.00034) (Miller et al., 2003). 
Brain tumor 
Note 
CrkII mRNA was detected both in normal brain and 
glioblastoma tissues, whereas crkI mRNA levels were 
quite low in normal brain and up-regulated in 
glioblastoma tissues.  
Expression of CrkI but not CrkII in glioblastoma 
U87MG cells induced transformation that stimulated 
cell migration and invasion concomitant with tyrosine 
phosphorylation of p130 Cas (Takino et al., 2003).  
Crk-knockdown cell lines of glioblastoma KMG4 was 
established by siRNA, and early phase of cell adhesion 
to laminin was found to be suppressed. Wound healing 
assay revealed the decreased cell motility in Crk 
knockdown cells, and suppression of both anchorage-
dependent and -independent growth were demonstrated 
in these cells. Furthermore, in vivo tumor forming 




Crk expression was targeted in the human ovarian 
cancer cell line MCAS through RNA interference, 
resulting in disorganized actin fibers, reduced number 
of focal adhesions, and decreased Rac activity in 
association with suppression of cell motility and 
invasion, and anchorage-dependent growth in soft agar.  
Tumor forming potential in nude mice was attenuated 
and intraperitoneal dissemination was not observed 
when Crk knockdown cells were injected into the 
peritoneal cavity (Linghu et al., 2006). 
Breast cancer 
Note 
CrkI/II knockdown resulted in a significant decrease in 
migration and invasion of multiple malignant breast 
and other human cancer cell lines (MDA-231, MDA-
435s, H1299, KB, and HeLa). Moreover, CrkI/II 
knockdown decreased cell spreading on extracellular 
matrix and led to a decrease in actin stress fibers and 
the formation of mature focal adhesions.  
Using immunohistochemistry, we show elevated 
CrkI/II protein levels in patients with breast 
adenocarcinoma (Rodrigues et al., 2005). 
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Synovial sarcoma 
Note 
Crk adaptor protein is required for the sustained 
phosphorylation of Gab1 in response to HGF, leading 
to the enhanced cell motility of human 
synovial sarcoma cell lines SYO-1, HS-SY-II, and Fuji. 
Crk knockdown by RNA interference disturbed this 
HGF-induced tyrosine phosphorylation of Gab1. The 
elimination of Crk in these cells induced the 
disorganization of actin cytoskeleton and complete 
abolishment of HGF-mediated Rac1 activation and cell 
motility. Furthermore, the depletion of Crk remarkably 
inhibited the tumor formation and its invasive growth 
in vivo (Watanabe et al., 2006). 
Oral cancer 
Note 
The expression of CRKII in 71 primary oral squamous 
cell carcinomas and 10 normal oral mucosal specimens 
was determined immunohistochemically, and the 
correlation of CRKII overexpression with 
clinicopathological factors was evaluated. 
Overexpression of CRKII was detected in 41 of 70 oral 
squamous cell carcinomas, the frequency being more 
significant than in normal oral mucosa. In addition, 
CRKII overexpression was more frequent in higher-
grade cancers according to the T classification, N 
classification, and invasive pattern. Moreover, RNAi-
mediated suppression of CRKII expression reduced the 
migration and invasion potential of an oral squamous 
cell carcinoma cell line, OSC20 (Yamada et al., 2011). 
Endometriosis 
Note 
The expression levels of miR-126 and and its putative 
target Crk mRNA were quantified using real time PCR 
in ectopic endometrium and eutopic endometrium in 
patients with endometriosis. The expression level of 
miR-126 was significantly downregulated in ectopic 
endometrium whereas the protein levels of Crk was 
increased. Thus, miR-126 may play an initial role in the 
development and progression of endometriosis (Liu et 
al., 2012). 
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